Kancera
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
KAN | ST
Overview
Corporate Details
- ISIN(s):
- SE0015658570 (+1 more)
- LEI:
- 5493002P3RCOFW6HI207
- Country:
- Sweden
- Address:
- Nanna Svartz väg 4, 171 65 SOLNA
- Website:
- https://kancera.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kancera is a clinical-stage biotechnology company that develops a new class of pharmaceuticals for life-threatening diseases with significant medical needs. The company specializes in small molecule drugs that target the fractalkine axis (CX3CR1 antagonists) to precisely control disease-promoting immune cells and cancer cells. Its pipeline includes drug candidates like rugocrixan and fosrugocrixan, which are in clinical trials for treating severe inflammatory conditions, resistant cancers, and preventing inflammation-related heart injuries.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Kancera filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kancera via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
